These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19851170)

  • 1. Doxorubicin-induced cardiac toxicity and cardiac rest gated blood pool imaging.
    Aiken MJ; Suhag V; Garcia CA; Acio E; Moreau S; Priebat DA; Chennupati SP; Van Nostrand D
    Clin Nucl Med; 2009 Nov; 34(11):762-7. PubMed ID: 19851170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
    Uyar D; Kulp B; Peterson G; Zanotti K; Markman M; Belinson J
    Gynecol Oncol; 2004 Jul; 94(1):147-51. PubMed ID: 15262133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography.
    Agarwala S; Kumar R; Bhatnagar V; Bajpai M; Gupta DK; Mitra DK
    J Pediatr Surg; 2000 Dec; 35(12):1786-9. PubMed ID: 11101737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary?
    Gill SE; Savage K; Wysham WZ; Blackhurst DW; Winter WE; Puls LE
    Gynecol Oncol; 2013 Jun; 129(3):544-7. PubMed ID: 23523653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapy-induced cardiac toxicity and management].
    Komagata H; Sakai H
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):787-92. PubMed ID: 12852345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy.
    Shureiqi I; Cantor SB; Lippman SM; Brenner DE; Chernew ME; Fendrick AM
    Br J Cancer; 2002 Jan; 86(2):226-32. PubMed ID: 11870511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Multiple gated acquisition.
    Sabel MS; Levine EG; Hurd T; Schwartz GN; Zielinski R; Hohn D; Edge SB
    Am J Clin Oncol; 2001 Aug; 24(4):425-8. PubMed ID: 11474280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoprotective agents for anthracyclines.
    Dorr RT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adriamycin cardiotoxicity amelioration by alpha-tocopherol.
    Krivit W
    Am J Pediatr Hematol Oncol; 1979; 1(2):151-3. PubMed ID: 543510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anthracyclines and the heart].
    Mazzarello GP; Morra L
    Recenti Prog Med; 1998 Sep; 89(9):459-64. PubMed ID: 9796378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate.
    Ganz WI; Sridhar KS; Forness TJ
    Am J Clin Oncol; 1993 Apr; 16(2):109-12. PubMed ID: 8452100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of anthracycline cardiotoxicity in children and adults.
    Grenier MA; Lipshultz SE
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of gated blood-pool SPECT cardiac measurements tested using a biventricular dynamic physical phantom.
    De Bondt P; Nichols K; Vandenberghe S; Segers P; De Winter O; Van de Wiele C; Verdonck P; Shazad A; Shoyeb AH; De Sutter J
    J Nucl Med; 2003 Jun; 44(6):967-72. PubMed ID: 12791827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data.
    De Leonardis V; Neri B; Bacalli S; Cinelli P
    Int J Clin Pharmacol Res; 1985; 5(2):137-42. PubMed ID: 3860480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracycline cardiotoxicity after breast cancer treatment.
    Hershman DL; Shao T
    Oncology (Williston Park); 2009 Mar; 23(3):227-34. PubMed ID: 19418823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiotoxicity of anthracycline cytostatic agents--a proposal for routine monitoring and supportive therapy].
    Svojgrová M; Slechtová J; Hůla J
    Vnitr Lek; 1991 Feb; 37(2):151-9. PubMed ID: 2021075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin).
    Machado V; Cabral A; Monteiro P; Gonçalves L; Providência LA
    Rev Port Cardiol; 2008 Oct; 27(10):1277-96. PubMed ID: 19178029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography.
    Lenk MK; Zeybek C; Okutan V; Ozcan O; Gökçay E
    Turk J Pediatr; 1998; 40(3):373-83. PubMed ID: 9763901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.